Search Results
Mar 02, 2026, 21:15 ET Royalty Pharma 任命孫鍶銘先生（Kenneth Sun）為高級副總裁兼亞洲區主管以擴大全球平台佈局
Pharma 與來自學術機構、研究醫院、非營利組織、中小型生物科技公司及全球領先製藥企業的創新者合作。Royalty Pharma 的特許權組合使其有權根據多項業界領先療法的銷售額直接獲得收益。目前，其特許權組合涵蓋 35 種以上的商業化產品，包括 Vertex 的 Trikafta 和 Alyftrek、GSK 的 Trelegy、Biogen 的 Tysabri 和 Spinraza、Roche 的 Evrysdi、Astellas 和 Pfizer 的 Xtandi、Johnson & Johnson 的 Tremfya、AbbVie 和 Johnson & Johnson 的 Imbruvica、Servier
More news about: Royalty Pharma
Feb 25, 2026, 03:24 ET Frontier Biotech und GSK schließen globale Exklusivlizenzvereinbarung für therapeutische Anwendungen mit kleinen interferierenden RNAs
Folgenden als „Frontier Biotech" oder „das Unternehmen" bezeichnet) hat einen exklusiven Lizenzvertrag mit GSK, einem globalen Biopharmaunternehmen, abgeschlossen. Gemäß den Vertragsbedingungen erhält GSK die weltweiten Exklusivrechte für die Entwicklung, Herstellung und Vermarktung von zwei Produkten aus
More news about: Frontier Biotechnologies Inc.
Feb 24, 2026, 20:30 ET Frontier Biotech et GSK concluent un accord de licence exclusif à l'échelle mondiale pour les thérapies fondées sur les petits ARN interférents (siRNA)
Frontier Biotechnologies Inc. (ci-après « Frontier Biotech » ou « la société ») a conclu un accord de licence exclusif avec GSK, une société biopharmaceutique mondiale. Selon les termes de l'accord, GSK obtiendra les droits exclusifs mondiaux pour développer, fabriquer et commercialiser deux des produits du pipeline
More news about: Frontier Biotechnologies Inc.
Feb 24, 2026, 10:01 ET Medical Cyclotron Market to Reach US$ 405.4 Million by 2033 Expands Amid Rising Demand for Advanced Diagnostics - Persistence Market Research
PfizerEli Lilly and CompanyAbbVie, Inc.Teva Pharmaceutical Industries Ltd.Johnson & JohnsonSanofiGSk plc.Bayer AGTONIX Pharmaceuticals Holdings CorpVirios Therapeutics, Inc.Aptinyx Inc.FSD PharmaBuy Now:
More news about: Persistence Market Research Pvt. Ltd.
Feb 24, 2026, 09:33 ET Frontier Biotech y GSK firman un acuerdo de licencia para terapias de ARN de interferencia pequeña
adelante, "Frontier Biotech" o "la Compañía") ha firmado un acuerdo de licencia exclusiva con GSK, compañía biofarmacéutica global. Según los términos del acuerdo, GSK obtendrá los derechos exclusivos a nivel mundial para desarrollar, fabricar y comercializar dos productos de ARN de interferencia pequeño
More news about: Frontier Biotechnologies Inc.
Feb 24, 2026, 08:01 ET START Appoints Dr. Frank Smith President of its XenoSTART Preclinical Research Business Unit
and Molecular Biology from Temple University, and an MBA from Villanova University. He joins XenoSTART following leadership roles at Charles River, GSK, and Champions Oncology, where he helped build and grow complex preclinical organizations serving global biopharma customers."XenoSTART sits at
More news about: The START Center for Cancer Research
Feb 24, 2026, 07:00 ET ERS Genomics launches new Early Access Express License
agricultural biotechnology, synthetic biology, including production of enzymes, food ingredients, and bio-based chemicals.Current ERS licensees include GSK, Merck, Bayer, Thermo Fisher Scientific, Corteva, Danaher, PerkinElmer, Charles River Laboratories, and Cargill. For more information, visit
More news about: ERS Genomics
Feb 24, 2026, 06:02 ET Frontier Biotech and GSK Enter Global Exclusive Licensing Agreement for Small Interfering RNA Therapeutics
Inc. (hereinafter referred to as "Frontier Biotech" or "the Company") has entered into an exclusive licensing agreement with GSK, a global biopharma company. Under the terms of the agreement, GSK will obtain exclusive worldwide rights to develop, manufacture, and commercialize two of Frontier Biotech's Small Interfering
More news about: Frontier Biotechnologies Inc.
Feb 24, 2026, 05:55 ET Frontier Biotech and GSK Enter Global Exclusive Licensing Agreement for Small Interfering RNA Therapeutics
Inc. (hereinafter referred to as "Frontier Biotech" or "the Company") has entered into an exclusive licensing agreement with GSK, a global biopharma company. Under the terms of the agreement, GSK will obtain exclusive worldwide rights to develop, manufacture, and commercialize two of Frontier Biotech's Small Interfering
More news about: Frontier Biotechnologies Inc.
Feb 19, 2026, 07:00 ET Altesa BioSciences Closes Oversubscribed $75 Million Series B Financing to Transform Treatment of Chronic Lung Diseases
following them and randomizing when they experience a rhinovirus infection. Dr. Katharine Knobil, Chief Medical Officer (CMO) of Altesa, and former CMO of GSK, will lead the investigation, expected to commence in Q2 2026. The CARDINAL study builds on Altesa's recently completed rhinovirus
More news about: Altesa Biosciences Inc.
Feb 17, 2026, 08:05 ET JAX-NYSCF Collaborative and GSK Announce Collaboration to Advance Translational Models for Neurodegenerative Disease Research
-- The Jackson Laboratory–New York Stem Cell Foundation Collaborative (JAX-NYSCF) today announced a five-year strategic research collaboration with GSK focused on advancing human cellular models of neurodegenerative disease, including Alzheimer's disease.
More news about: The Jackson Laboratory-New York Stem Cell Foundation Collaborative
Feb 17, 2026, 06:00 ET IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
with our partner, Servier.In December 2025, GlaxoSmithKline (GSK) notified IDEAYA of its intention to terminate the Collaboration, Option and License Agreement, dated June 15, 2020. Pursuant to the terms of the Agreement, GSK will transfer the Werner Helicase (IDE275) and Pol Theta (IDE705) clinical
More news about: IDEAYA Biosciences, Inc.
Feb 11, 2026, 21:59 ET ACROBiosystems fördert Innovationen bei JPM Spotlight-Sessions von bioSeedin und unterstützt strategisch den Aufbau globaler Partnerschaften
teil, darunter Pfizer, Roche, AbbVie, Daiichi-Sankyo, Takeda, bioSeedin, Bayer, Hengrui Pharma, RA Capital Management, Pacific Bridge NY, Hansoh Pharma, GSK, Boehringer Ingelheim, PIVOTAL BIOVENTURE PARTNERS und Fangda Partners.Adagene, EpimAb Biotherapeutics, Excalipoint Therapeutics, Convalife Pharmaceuticals,
More news about: ACROBiosystems Group
Feb 11, 2026, 21:56 ET ACROBiosystems stimule l'innovation au cours du JPM Spotlight de bioSeedin, en soutenant stratégiquement l'établissement de partenariats mondiaux
notamment Pfizer, Roche, AbbVie, Daiichi-Sankyo, Takeda, bioSeedin, Bayer, Hengrui Pharma, RA Capital Management, Pacific Bridge NY, Hansoh Pharma, GSK, Boehringer Ingelheim, PIVOTAL BIOVENTURE PARTNERS et Fangda Partners.Adagene, EpimAb Biotherapeutics, Excalipoint Therapeutics, Convalife Pharmaceuticals,
More news about: ACROBiosystems Group
Feb 11, 2026, 20:51 ET Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders?
RAPT Therapeutics, Inc. (NASDAQ: RAPT)'s sale to GSK plc for $58.00 per share. If you are a RAPT shareholder,
More news about: Halper Sadeh LLP
Feb 11, 2026, 20:02 ET Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders?
RAPT Therapeutics, Inc. (NASDAQ: RAPT)'s sale to GSK plc for $58.00 per share. If you are a RAPT shareholder,
More news about: Halper Sadeh LLP
Feb 11, 2026, 17:31 ET EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight
Lilly and Company, Merck, Regeneron/Sanofi, Ono Pharmaceutical, Novartis, Genentech/Roche, Amgen, Chugai Laboratories, Moderna Therapeutics, Pfizer, GSK among others.
More news about: DelveInsight Business Research, LLP
Feb 11, 2026, 12:07 ET ACROBiosystems impulsa la innovación en JPM Spotlight de bioSeedin
incluyendo a Pfizer, Roche, AbbVie, Daiichi-Sankyo, Takeda, bioSeedin, Bayer, Hengrui Pharma, RA Capital Management, Pacific Bridge NY, Hansoh Pharma, GSK, Boehringer Ingelheim, PIVOTAL BIOVENTURE PARTNERS y Fangda Partners.Adagene, EpimAb Biotherapeutics, Excalipoint Therapeutics, Convalife
More news about: ACROBiosystems Group
Feb 11, 2026, 04:00 ET ACROBiosystems Powers Innovation at bioSeedin's JPM Spotlight, Strategically Supporting Global Partnership Forging
including Pfizer, Roche, AbbVie, Daiichi-Sankyo, Takeda, bioSeedin, Bayer, Hengrui Pharma, RA Capital Management, Pacific Bridge NY, Hansoh Pharma, GSK, Boehringer Ingelheim, PIVOTAL BIOVENTURE PARTNERS, and Fangda Partners.Adagene, EpimAb Biotherapeutics, Excalipoint Therapeutics, Convalife Pharmaceuticals,
More news about: ACROBiosystems Group
Feb 06, 2026, 16:29 ET Halper Sadeh LLC is Investigating Whether NWE, DHIL, RAPT are Obtaining Fair Prices for its Shareholders
click here to learn more about your rights and options.RAPT Therapeutics, Inc. (NASDAQ: RAPT)'s sale to GSK plc for $58.00 per share. If you are a RAPT shareholder,
More news about: Halper Sadeh LLP
Feb 05, 2026, 09:00 ET The J.M. Smucker Co. Announces the Election of Katie Williams to Chief Marketing Officer
health brands such as Advil®, Sensodyne®, Tums®, EmergenC®, and Centrum®. Before Haleon spun-off from parent company GSK in 2022, Williams served as U.S. Chief Marketing Officer for GSK, and earlier in her career she held marketing leadership positions for Mondelēz and Kraft-Heinz. "Throughout my
More news about: The J.M. Smucker Co.
Feb 05, 2026, 04:00 ET BioPhorum announces formation of Strategic Advisory Board to accelerate industry collaboration
& Supply, GSK- Narendra has 20+ years of experience leading biopharmaceutical research and development groups. At GSK he manages a group of world class scientists responsible for developing cell lines, process, product, and analytical methods of all biopharmaceuticals in the GSK R&D portfolio.Peter
More news about: BioPhorum
Feb 03, 2026, 08:05 ET Rigel Appoints Michael P. Miller to the Board of Directors
included Senior Vice President, Chief Commercial Officer of Connetics Corporation, a specialty pharmaceutical company acquired by Stiefel Laboratories (GSK); Vice President of the of ALZA Corporation, a pharmaceutical company acquired by Johnson & Johnson; and various sales and marketing positions at
More news about: Rigel Pharmaceuticals, Inc.
Feb 02, 2026, 15:30 ET $HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger--JHG, FOLD, RAPT, and EXAS
RAPT) related to its sale to GSK plc. Under the terms of the proposed transaction, RAPT shareholders are expected to receive $58.00 in cash for each share of RAPT common stock.ACT
More news about: Monteverde & Associates PC
Feb 02, 2026, 10:00 ET ACROBiosystems Powers Innovation at bioSeedin's JPM Spotlight, Strategically Supporting Global Partnership Forging
representatives from Pfizer, Roche, AbbVie, Daiichi-Sankyo, Takeda, bioSeedin, Bayer, Hengrui Pharma, RA Capital Management, Pacific Bridge NY, Hansoh Pharma, GSK, Boehringer Ingelheim, PIVOTAL BIOVENTURE PARTNERS, and Fangda Partners.Companies including Adagene, EpimAb Biotherapeutics, Excalipoint Therapeutics,
More news about: ACROBiosystems